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Summary. — Nano-structures for photodynamical therapy can be assembled start-
ing from a photosensitizer (PS) and a protein-based carrier, exploiting hydrophobic
interactions. These chemical constructs preserve the PS photophysical and pho-
tosensitizing properties by preventing aggregation of non water-soluble PSs. This
allows to obtain bio-compatible nanostructures that enhance the bio-availability of
the PS. We demonstrate the interaction of Hypericin (Hyp), a naturally occurring
PS that generates singlet oxygen with a high quantum yield, with two different pro-
teins, apo-myoglobin and β-lactoglobulin. The constructs are highly effective against
Gram-positive bacteria (S. aureus and B. subtilis). Interestingly, Hyp both free and
bound to the protein can be exploited in super-resolution STED fluorescence mi-
croscopy, allowing for an accurate localization at cellular level of the PS and the pho-
toinduced oxidation effects. Therefore, these structures show a double functionality,
both therapeutic (based on photosensitization) and diagnostic (based on imaging),
so that they can be considered theranostic agents. In conclusion, we demonstrate the
potential of the protein-based nanostructures as water soluble and bio-compatible
systems that can be relevant for applications in antimicrobial decontamination, both
in clinical and in food and food-processing environment applications.
1. – Introduction
Recently, the term “theranostic” has been introduced in order to indicate an emerging
research area in nano-medicine with the aim to develop chemical constructs that combine
targeting, therapeutic and diagnostic functions within a single nanoscale complex [1].
“Classical” drug delivery systems, as liposomes, polymers, micelles, nanoparticles and
antibodies have been loaded both with a drug and an agent for localization, exploiting
photoluminescence of fluorophores or their properties as magnetic resonance constrast
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Fig. 1. – Simplified Jablonski diagram for the photosensitization of molecular oxygen. Non-
radiative (inter-system crossing and quenching), and absorption transitions are indicated with
black dashed arrows. S and T labels denote respectively singlet and triplet spin multiplicity of
the PS.
agents [2]. Particularly interesting are the design and synthesis of nanoshell-based ther-
anostic agents in order to improve the balance between efficacy and toxicity [3].
This theranostic approach can be considered for applications in photodynamic therapy
(PDT) which is a clinically approved practice that can exert a selective cytotoxic activity
toward malignant cells and pathogenic micro-organisms. PDT exploits the photodynamic
effect, which implies the use of otherwise non toxic molecules, named photosensitizers
(PSs), and visible light in the presence of molecular oxygen, to produce reactive oxygen
species like free radicals or singlet oxygen, which result in cellular toxicity [4]. The
oxidative damage or stress caused by the reactions with lipids, proteins or DNA are
relevant and produce cellular death [5-7]. The essential photophysical features of the
process are sketched in fig. 1.
In a photosensitization process, a PS is excited to an electronically excited state, usu-
ally a singlet state, by the absorption of a UV-visible photon and then with a significant
probability undergoes an intersystem crossing transition to an excited triplet state (T1).
T1 has a lifetime longer than the one of the excited singlet states and the correct spin
multiplicity, that allows a photosensitized reaction with molecular oxygen. In fact, if T1
has a suitable energy (at least 158 kJ/mol) an energy transfer process may occur: the PS
returns to its initial singlet ground state while the molecular oxygen is simultaneously
excited to an electronically excited singlet state (either 1Σ+g or
1Δg). The relaxation from
1Σ+g to
1Δg is very fast in solution, therefore the final product of the reaction will always
be the “singlet oxygen”, simply indicated as 1O2. The energy transfer process is called
Dexter-type or electron-exchange mechanism, and consists in the simultaneous transfer
of two excited electrons from one species to the other, so that there is no net charge
transfer. The process is spin-allowed so it occurs with relatively high probability, but
it requires a collision between the two partners since the wave functions of the involved
electrons must overlap [8].
The effectiveness of a PS, measured by the 1O2 photosensitization quantum yield ΦΔ,
can be expressed in general as
(1) ΦΔ = ΦT SΔ,
where ΦT is the quantum yield for the triplet state formation and SΔ the efficiency of
the energy transfer process leading to 1O2 generation.
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It is evident that devising an effective photosensitizer implies first of all optimizing the
photophysical parameters to maximize formation of productive states (high photosensi-
tization quantum yield), but also assuring no dark toxicity and high molar extinction
coefficient in the red/NIR spectral range to maximize the penetration in tissues and high
bio-availability. This latter feature is closely related to the extent of the 1O2 diffusion
that can be estimated using the equation
(2) d = (6Dτ)0.5,
where d is the radial distance over a time τ and D is the diffusion coefficient. Considering
the lifetime of 1O2, a PS can produce an effective oxidative damage only if the photo-
sensitization reaction is induced within about 100 nm from the target [9]. The issue is
crucial for the applications because PSs are usually non soluble molecules, which in an
aqueous solution form aggregates that quench the PS fluorescence emission and triplet
state, preventing the production of 1O2. Hence the requirement of finding vehicles able
to bind the PS and transport it to the target, either a tumor cell or a bacterium.
Exploiting the fluorescence emission from PS molecules for imaging purposes turns
the compound into a theranostic agent, being at the same time a pro-drug and a probe for
imaging. This opens the opportunity for monitoring drug delivery, release and efficacy
of these compounds, through direct visualization with fluorescence microscopy of the
distribution of the drug and the damages induced upon illumination.
A key point remains the biocompatibility of the nanocarrier. To address this issue,
we have recently proposed some proteins as natural candidates for transporting a hy-
drophobic drug such as a PS molecule. They offer important advantages related to the
fact that a protein can be easily used and produced, selected to be biocompatible for
applications in a particular environment, tailored to the target organism, and possibly
engineered.
This approach can be considered not only for tumor PDT, but also for antimicrobial
PDT (aPDT), originally developed in the ‘90s and now gaining growing interest for the
treatment of localized infections [10,11]. Bacterial infections constitute a steadily growing
problem in clinical practice, due to natural selection and misuse of antibiotics that lead
to an increasing number of resistant bacteria, which renders the available drugs less
effective or even useless. The recent report of the WHO, which predicts a post-antibiotic
era in which minor infections or injuries may become a serious problem, underlines the
demand of the development of novel antimicrobial treatment strategies [12]. Besides the
increased prevalence of antimicrobial resistance, complex infection and immune evasion
strategies of bacterial pathogens pose a serious threat for the affected patients and aPDT
constitutes an important alternative treatment against resistant infections.
Moreover, the interest concerning aPDT has been recently extended beyond the clin-
ical applications and one of the most promising is the decontamination of food and food-
processing environment from common pathogen microorganisms (fungi, yeasts, molds
and bacteria, often grown in bio-film). This is particularly important for not-cooked
food like fruits, vegetables, sprouts, cheese and cold cuts. In these cases, an important
issue is the biocompatibility of the photosensitizing agent, that must have low impact on
the quality of the product [13,14].
In the present paper, we summarize two examples of use of different protein scaffolds as
bio-compatible nanocarriers for aPDT, loaded with a natural photosensitizer, Hypericin
(Hyp), as reported in our recent papers [15-18]. We chose two proteins, wide-spread and
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well-known representative of their respective families: apomyoglobin (apoMb), i.e. myo-
globin without its physiological cofactor (heme), from horse heart, and β-lactoglobulin
B (βLG), a dimeric protein belonging to the lipocalin family and the most abundant
protein in the whey of cow milk. They can be both considered as carrier proteins, even
if they are extremely different from several points of view like structure, origin, function
and solvation properties.
2. – Materials and methods
The details concerning the preparation of samples, photoinactivation experiments,
spectroscopic and imaging measurements have been thoroughly described in our previous
works [15-18]. The only parameter determined in this work is the triplet quantum yield
of Hyp bound to apoMb. It has been estimated from laser flash photolysis measurements
using a comparative method with Hyp in dimethyl sulfoxide (DMSO) as a reference.
3. – Results and discussion
Hypericin (Hyp) is a naturally occurring PS, extracted from the plant Hypericum
perforatum (St. John’s wort), which has already proved to be efficient as an antibacte-
rial [19] antiviral [20] and antifungal [21] photodynamic agent. The idea we are pursuing
in these years is to design protein-based nanostructures for the delivery of Hyp as self-
assembled, photophysically active supramolecular structures taking advantage of simple
hydrophobic effect.
Hyp has a very similar chemical structure for size, shape hydrophobicity and sym-
metry to the heme and this fact suggests that it can form stable complex with apoMb.
Indeed, computational modelling demonstrated that the hydrophobic cavity, which usu-
ally contains the heme in apoMb, can similarly host Hyp (fig. 2(A)). On the contrary,
βLG shows a very different fold, typical of lipocalins, able only to accommodate linear
hydrophobic molecules. However, forming dimers (2βLG) at its physiologically concen-
tration [22], 2βLG is able to bind Hyp in correspondence to the clefts at the interface of
the two monomers. In fact, as demonstrated by docking and MD simulations, a narrow
cleft displays a larger affinity for Hyp and can accommodate the PS only as a monomer,
whereas a wider cleft allows for the binding of dimeric PS molecules. In both cases,
MD simulations show that slightly different orientations of PS within the pockets are
possible (fig. 2(B)). It is important to note that if the self-assembling of the complex
is a more complicated process for 2βLG than for apoMb, the interest of the lipocalin
structure concerns the fact that more than one PS molecule can be transported and that
2βLG-Hyp can represent a bio-compatible system for antimicrobial decontamination in
the dairy industry, considering that βLG is the most abundant protein in bovine milk
whey [23].
Hyp is insoluble in water, while it is highly soluble in DMSO and ethanol. How can
we demonstrate experimentally the formation of a self-assembled nanostructure between
the protein (apoMb or 2βLG) that we want to use as a “vehicle” and Hyp as the “passen-
ger” in aqueous PBS buffer? We can monitor spectroscopically this “vehicle-passenger”
interaction by following the changes in the photophysical properties of Hyp. In fact, in
DMSO and ethanol Hyp displays a well structured absorbance spectrum and an equally
structured fluorescence emission spectrum, as shown in fig. 2(C). This emission is strongly
reduced in PBS where Hyp forms aggregates and the bands in the absorbance spectrum
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Fig. 2. – (A) Solvent-accessible surface of apoMb highlighting the heme-pocket suitable to bind
Hyp. (B) The protein structure of 2βLG bound to Hyp molecules as monomers in the narrow
cleft, and either monomers or dimers in the wide cleft. Hyp molecules are shown as sticks.
(C) Fluorescence excitation spectrum of a 1 μM solution of Hyp in DMSO (gray solid line) and
fluorescence emission spectra for Hyp in DMSO (black solid line), Hyp bound to apoMb (black
dotted line) and in PBS buffer (black dashed line).
broaden. When a protein (apoMb or 2βLG) is added, Hyp recovers spectral features re-
sembling those observed for monomeric Hyp dissolved in DMSO, i.e. sharper absorption
bands and a more intense and structured fluorescence emission (fig. 2(C)). The recovery
of spectral properties of monomeric Hyp is practically complete in apoMb-Hyp, whereas
it is only partial in 2βLG-Hyp. This indicates that only in presence of apoMb a large
fraction of Hyp molecules is not aggregated, it behaves as a monomeric species and is well
solubilized by the interaction with the protein, where the PS senses a local environment
with characteristics of polarity similar to those experienced in DMSO or ethanol. In
other words, Hyp is accommodated in the hydrophobic cavity, vacated by removing the
heme.
Further confirmations to complex formation come from steady-state fluorescence
anisotropy (fig. 3(A)) and PS triplet state decay as monitored by triplet-triplet tran-
sient absorption (fig. 3(B)).
In fact, as can be observed in fig. 3(A), Hyp dissolved in DMSO shows zero anisotropy
Fig. 3. – (A) Fluorescence steady-state anisotropy spectra of Hyp in DMSO (gray line) and
apoMb-Hyp (black line) in PBS. (B) Triplet-triplet transient absorption kinetics of Hyp in
DMSO (solid gray line), apoMb-Hyp (solid black line) and 2βLG-Hyp (dotted black line) in
PBS. Fitting curves are superimposed to the experimental data (light gray lines). T = 20 ◦C.
Adapted from ref. [18].
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as a consequence of the rapid rotation of the molecule in solution which removes the initial
orientation of the excited states dipole moment. Conversely, in the presence of apoMb,
the anisotropy is non-zero meaning that Hyp rotation is much slower and the molecule
holds a preferential orientation within its lifetime of fluorescence emission. This is a
consequence of the interaction of Hyp with the cavity of apoMb, that induces constraints
limiting the rotational diffusion of the molecule within its emission lifetime. Similar
results are obtained for 2 βLG (data not shown).
Moreover, fig. 3(B) shows that the lifetime of triplet state of Hyp when apoMb or
2βLG are added becomes longer. This demonstrates that in apoMb-Hyp and 2βLG-Hyp
the PS is protected from the environment and confirms the occurred self-assembling of
the complexes.
The change in spectral properties of Hyp upon binding to the proteins provides a
means to evaluate the affinity of the dye for the proteins. The value of the equilibrium
constant for the formation of apoMb-Hyp and 2βLG-Hyp complexes is obtained by moni-
toring the fluorescence emission of Hyp at increasing concentration of the protein in PBS.
Fitting the total fluorescence emission to the experimental data using eq. 1 reported in
ref. [15], a value of Kd = (4.2± 0.8) μM and Kd = (0.71± 0.03) μM can be estimated for
apoMb-Hyp and 2βLG-Hyp, respectively.
In order to use Hyp bound to a protein as a theranostic agent, two conditions should be
verified. The first is that it is important that Hyp continues to be a fluorescence imaging
probe, i.e. that its fluorescence quantum yield (ΦF ) remains to a significant level. Using
a comparative method, where the emission of a molecule of known ΦF is compared to the
emission of the studied molecule, this parameter can be evaluated. The estimated value
demonstrates that the emission properties of Hyp are preserved significantly when the
PS forms a complex with apoMb (ΦF = 0.14±0.02), and only partially when it is bound
to 2βLG (ΦF = 0.03 ± 0.01). The second question is: can the molecule sensitize 1O2 to
a respectable extent when it is bound in the cavity of a protein? In other words, does
the PS continue to produce singlet oxygen? Production of reactive singlet oxygen can
be demonstrated by observation of its specific phosphorescence at 1275 nm. From the
time-resolved near-IR luminescence emission (1275 nm) by solutions of Hyp in DMSO,
and the complexes of Hyp with the proteins in PBS, the lifetimes of the triplet state
of PS and 1O2 are obtained. Moreover, the quantum yield of 1O2 photosensitization is
readily calculated by comparison with a reference compound (Rose Bengal in PBS for
apoMb-Hyp).
As a summary, photophysical properties of Hyp in DMSO and of the complexes are
reported in table I. It has to be noted that 2βLG-Hyp has a smaller ability than free Hyp
and apoMb-Hyp to emit fluorescence (lower ΦF), excite the triplet state (lower ΦT), and
produce singlet oxygen (lower ΦΔ). These results are the consequence of the fact that a
fraction of Hyp is likely not fully monomeric and is embedded within an environment less
polar than water, but not so much as in the hydrophobic heme cavity of apoMb. However,
overall this characterization indicates that the shielding of Hyp from the solvent, due to
the protein scaffold, does not preclude the formation of 1O2, in particular for apoMb-
Hyp, and demonstrates the potential of the protein-based nanostructures as water soluble
and bio-compatible therapeutic agent for photosensitization-based applications.
As observed above, an accurate localization of the photosensitizing agent at the cel-
lular level is extremely important for studying the effect of the photooxidation, since it
reveals where the damage will be first induced. Conventional fluorescence microscopy is
the easiest and more direct technique to image the distribution of a PS in a cell, but its
resolution is limited by the diffraction of light to a few hundred nanometers. However,
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Table I. – Photophysical parameters of Hyp in DMSO, apoMb-Hyp and 2βLG-Hyp in PBS.
The parameters for Hyp and apoMb-Hyp are from ref. [18], for 2βLG-Hyp from ref. [17], except
where otherwise indicated.
ΦF τT (μs) ΦT τΔ (μs) ΦΔ
Hyp 0.35 ± 0.02[24] 1.6 ± 0.1a 0.35[25] 5.5 ± 0.1 0.28 ± 0.05b
apoMb-Hyp 0.14 ± 0.02 11.6 ± 0.1 0.13 ± 0.04a,c 2.4 ± 0.4 0.14 ± 0.03
2βLG-Hyp 0.03 ± 0.01 10 ± 2 0.050 ± 0.002 2.3 ± 0.1 0.065 ± 0.010
a From Laser Flash Photolysis data.
b from NIR Phosphorescence data.
c Parameter determined in this work.
both free Hyp and Hyp bound to a protein based nanocarrier are amenable to be used
as fluorescent reporters in super-resolution STED (Stimulated Emission Depletion) mi-
croscopy [26]. Figure 4 displays sample images of Staphylococcus aureus incubated with
apoMb-Hyp and collected using confocal microscopy (panel (A)) and STED nanoscopy
(panel (B)). Both images show that the cells become fluorescent after the incubation
period and thus that the protein-based carrier delivered Hyp to the cells, preventing ag-
gregation. However, the image undergoes a remarkable improvement in resolution when
the STED beam is turned on. This allows to determine with higher precision the distri-
Fig. 4. – Comparison between S. aureus images collected with confocal microscopy (A) and
with STED nanoscopy (B) after incubation with apoMb-Hyp. The gray and the black intensity
profiles (C) were measured along the white segment in A and B, respectively. Images are
collected under excitation at 566 nm and detection at 605–670 nm, with STED beam at 715 nm.
Comparison between the light dose effects on photoinactivation of (D) Hyp and apoMb-Hyp on
S. aureus, (E) Hyp and apoMb-Hyp on B. subtilis and (F) Hyp and 2βLG-Hyp on S. aureus.
Hyp is in white and Hyp bound to the protein in gray. Adapted from ref. [18].
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bution of the PS on bacterial cell wall, even if the improved resolution is not sufficient
to determine the finer distribution of the PS on the components that constitute the cell
wall, like the peptidoglycan layer or the membranes. The improvement in resolution can
be better appreciated by inspection of the fluorescence emission profile along the cross
section of a cell, as indicated in fig. 4(C). This reveals the accumulation of Hyp on an
outer component of the cell, having a width in the order of 90 nm, compatible with the
cell wall of the Gram-positive bacteria, and in areas connected to processes of cellular
growth and division (not recognizable in the blurred confocal images, fig. 4 (A)).
Although a very similar distribution of Hyp (and complexes) on three bacterial types,
belonging to Gram-positive (Bacillus subtilis and S. aureus) and Gram-negative (E. coli)
class, the effect induced by irradiation on cells is remarkably different. The results of the
photoinactivation experiments showing the bacterial cell viability after the phototreat-
ment are summarized in fig. 4(D), 4(E), 4(F) and point out a major difference of efficacy
between Gram-positive and Gram-negative bacteria. Considering apoMb-Hyp, the lower
green light dose used (18 J cm−2) is enough to decrease the number of colony forming
units by 5 log units for S. aureus. Conversely, no sizeable effects are observed on the
Gram-negative E. coli. The case of the Gram-positive B. subtilis appears intermedi-
ate, with an effect of light exposure inducing about a 2 orders of magnitude decrease in
the number of bacterial colony forming units for both Hyp delivered with apoMb-Hyp
and free Hyp. The different response of Gram-positive and Gram-negative bacteria to
photosensitization-based treatment was reported in the literature for other PS molecules
and has been correlated to the different structure of the bacterial cell wall [27], that is
less permeable in the case of Gram-negative. Considering 2βLG-Hyp, the experiments
were performed only on S. aureus, due to the relevance of infection by this bacterium in
the dairy food chain, and demonstrate that the complex is able to inactivate S. aureus
bacteria (about 5 logs).
Remarkably, in both cases (apoMb-Hyp and 2βLG-Hyp) the bacterial phototoxicity
of complexes is not much different from that of free Hyp, but two major advantages of the
use of PS loaded to a protein-nanocarrier can be identified. First, the dark toxicity ap-
pears lower for Hyp delivered with a protein than for free Hyp. Second, free Hyp must be
dispensed as a concentrated solution in DMSO, which is decisively much less compatible
with the use in clinical applications (apoMb-Hyp) or in food industry (2βLG-Hyp).
4. – Conclusion
We have demonstrated that the binding of a fluorescent PS, like Hyp, to a pro-
tein (apoMb and 2βLG) preserves the photophysical and photosensitizing properties of
the active molecule. Therefore, the nanostructured system offers, in a single molecu-
lar species, a therapeutic functionality, based on photosensitization, and a diagnostic
functionality based on fluorescence emission. These protein-based nanocarriers show the
enormous advantage to be bio-compatible systems, that promote the solubilization of
the PS, thus enhancing their photoactivity and increasing their bio-availability, funda-
mental features for application in the clinical practice and in food decontamination. The
studied nanostructures demonstrate their significant efficacy on Gram-positive bacteria,
but further studies related to a finer knowledge of PS distribution at cellular level may
allow for a better comprehension of the different effect of aPDT on Gram-positive and
Gram-negative bacteria.
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